152 related articles for article (PubMed ID: 421202)
21. Interleukin-2 expanded lymphocytes from lymph node and tumor biopsies of human renal cell carcinoma, breast and ovarian cancer.
Bouet-Toussaint F; Genetel N; Rioux-Leclercq N; Bansard JY; Levêque J; Guillé F; Patard JJ; Lesimple T; Catros-Quemener V
Eur Cytokine Netw; 2000 Jun; 11(2):217-24. PubMed ID: 10903800
[TBL] [Abstract][Full Text] [Related]
22. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
[TBL] [Abstract][Full Text] [Related]
23. IL-2 enhances standard IFNgamma/LPS activation of macrophage cytotoxicity to human ovarian carcinoma in vitro: a potential for adoptive cellular immunotherapy.
Han X; Wilbanks GD; Devaja O; Ruperelia V; Raju KS
Gynecol Oncol; 1999 Nov; 75(2):198-210. PubMed ID: 10525372
[TBL] [Abstract][Full Text] [Related]
24. Detection of tumor-specific antigens in human mucinous cystadenocarcinoma of the ovary by immunodiffusion.
Chow SN; Chiang WT; Wei PY
Int J Gynaecol Obstet; 1976; 14(3):280-4. PubMed ID: 13019
[TBL] [Abstract][Full Text] [Related]
25. [In vitro study of 6B11GM to induce cellular immunity in patients with ovarian carcinoma].
Yang F; Qian H; Feng J
Zhonghua Fu Chan Ke Za Zhi; 1999 Nov; 34(11):660-3. PubMed ID: 11479947
[TBL] [Abstract][Full Text] [Related]
26. Lymphokine-activated killer activity of tumor-associated and peripheral blood lymphocytes isolated from patients with ascites ovarian tumors.
Allavena P; Zanaboni F; Rossini S; Merendino A; Bonazzi C; Vassena L; Mangioni C; Mantovani A
J Natl Cancer Inst; 1986 Oct; 77(4):863-8. PubMed ID: 3489856
[TBL] [Abstract][Full Text] [Related]
27. [Induction of T cell responses against autologous ovarian cancer by anti-idiotype minibody-pulsed dendritic cells].
Yang WL; Cui H; Feng J; Chang XH; Fu TY; Ye X; Zhang H; Li XP; Wen HW; Feng LM; Tong CR
Ai Zheng; 2004 Dec; 23(12):1639-45. PubMed ID: 15601552
[TBL] [Abstract][Full Text] [Related]
28. Intraperitoneal recombinant gamma-interferon in patients with recurrent ascitic ovarian carcinoma: modulation of cytotoxicity and cytokine production in tumor-associated effectors and of major histocompatibility antigen expression on tumor cells.
Allavena P; Peccatori F; Maggioni D; Erroi A; Sironi M; Colombo N; Lissoni A; Galazka A; Meiers W; Mangioni C
Cancer Res; 1990 Nov; 50(22):7318-23. PubMed ID: 2121337
[TBL] [Abstract][Full Text] [Related]
29. Association of HER2/neu expression with sensitivity to tumor-specific CTL in human ovarian cancer.
Yoshino I; Peoples GE; Goedegebuure PS; Maziarz R; Eberlein TJ
J Immunol; 1994 Mar; 152(5):2393-400. PubMed ID: 8133050
[TBL] [Abstract][Full Text] [Related]
30. Generation of monoclonal antibodies reacting with human epithelial ovarian cancer.
Tagliabue E; Mènard S; Della Torre G; Barbanti P; Mariani-Costantini R; Porro G; Colnaghi MI
Cancer Res; 1985 Jan; 45(1):379-85. PubMed ID: 3965146
[TBL] [Abstract][Full Text] [Related]
31. Detection of human ovarian tumor-associated antigens by antibodies isolated from ovarian carcinoma ascitic fluid.
Rao GS; Hanjani P
Am J Obstet Gynecol; 1988 Jul; 159(1):94-8. PubMed ID: 3394756
[TBL] [Abstract][Full Text] [Related]
32. [Relationship between interleukin-10 level in ascites of patients with primary ovarian epithelial carcinoma and immune defect in peritoneal cavity].
Zhou JW; Cheng Q; Xie X; Chen HZ; Ye DF; Lu WG
Ai Zheng; 2004 May; 23(5):573-6. PubMed ID: 15142457
[TBL] [Abstract][Full Text] [Related]
33. Interferon effect on cytotoxicity of peripheral blood and tumor-associated lymphocytes against human ovarian carcinoma cells.
Allavena P; Introna M; Sessa C; Mangioni C; Mantovani A
J Natl Cancer Inst; 1982 Apr; 68(4):555-62. PubMed ID: 6175786
[TBL] [Abstract][Full Text] [Related]
34. TCR V beta 3+ and V beta 6+ CTL recognize tumor-associated antigens related to HER2/neu expression in HLA-A2+ ovarian cancers.
Peoples GE; Yoshino I; Douville CC; Andrews JV; Goedegebuure PS; Eberlein TJ
J Immunol; 1994 May; 152(10):4993-9. PubMed ID: 7909829
[TBL] [Abstract][Full Text] [Related]
35. Monoclonal antibodies recognizing tumor-associated antigen of human ovarian mucinous cystadenocarcinomas.
Bhattacharya M; Chatterjee SK; Barlow JJ; Fuji H
Cancer Res; 1982 May; 42(5):1650-4. PubMed ID: 6175395
[TBL] [Abstract][Full Text] [Related]
36. Studies on the induction and expression of T cell-mediated immunity. XIV. Antigen-nonspecific oxidation-dependent cellular cytotoxicity (ODCC) mediated by sodium periodate oxidation of cytotoxic T lymphocytes.
Fan J; Bonavida B
J Immunol; 1983 Sep; 131(3):1426-32. PubMed ID: 6193189
[TBL] [Abstract][Full Text] [Related]
37. Morphological and immunological heterogeneity of human ovarian neoplasms.
Harłozińska A; Rabczyński J; Bar JK; Richter R
Arch Immunol Ther Exp (Warsz); 1991; 39(4):419-29. PubMed ID: 1821619
[TBL] [Abstract][Full Text] [Related]
38. Immunological aspects of gynecological malignancies.
DiSaia PJ
J Reprod Med; 1975 Jan; 14(1):17-20. PubMed ID: 1110478
[TBL] [Abstract][Full Text] [Related]
39. Cytokine production by T-cell lines derived from tumor-infiltrating lymphocytes from patients with ovarian carcinoma: tumor-specific immune responses and inhibition of antigen-independent cytokine production by ovarian tumor cells.
Kooi S; Freedman RS; Rodriguez-Villanueva J; Platsoucas CD
Lymphokine Cytokine Res; 1993 Dec; 12(6):429-37. PubMed ID: 8123759
[TBL] [Abstract][Full Text] [Related]
40. Tumor-associated antigen Ca 125 before and during the treatment of ovarian carcinoma.
Kivinen S; Kuoppala T; Leppilampi M; Vuori J; Kauppila A
Obstet Gynecol; 1986 Apr; 67(4):468-72. PubMed ID: 3008051
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
